Latest Whitepapers

Innovation is key for any biopharmaceutical and biotechnology company. Whilst the demand for infectious disease prevention continues to grow, so does the pressure on these companies to deliver innovative solutions.

Recent technological advancements have made single-cell sequencing an increasingly powerful tool for understanding biology and cellular function, disease diagnosis, therapy response prediction, and treatment selection.

Only a small amount of cell-free DNA (cfDNA) can be found in circulation, therefore efficient and highly sensitive technologies such as next-generation sequencing (NGS) are typically being used to detect this biomarker.

Biofuels have garnered increased attention due to the economic and environmental concerns associated with petroleum-based fuel.

CRISPR/Cas9 has revolutionized the field of genome editing by increasing the efficiency, multiplex capability and ease of use like never before.

Many regulatory guidelines state that cell banks and cultures used in the production of biologics must be tested for mycoplasma. Mycoplasma infections can cause severe problems in manufacturing as these organisms can alter DNA, RNA and modify host cell plasma membrane antigens.

Serious infectious disease outbreaks have been an ever-present threat throughout human history and, driven by factors such as increasing globalization, population growth, urbanization and climate change, that threat is increasing.

GeoMx® Human Whole Transcriptome Atlas

Traditional gene expression technologies are unable to capture heterogeneity of the transcriptome with spatial context.

Spatially resolved biology allows researchers to study cells in the context of their tissue microenvironment, enabling a fuller appreciation of cellular function.

While next-generation sequencing is becoming increasingly routine in cancer research laboratories, it fails to address a number of key genomic drivers or markers of cancer, such as structural variations, DNA methylation and transcript isoforms.